Skip to content
Search

Latest Stories

MSN & Lunts Pharmacy Group acquires Bicton Heath Pharmacy in Shropshire

MSN & Lunts Pharmacy Group acquires Bicton Heath Pharmacy in Shropshire

The UK pharmacy market is likely witnessing the return of small-medium size group operators to the buying landscape  

The MSN & Lunts Pharmacy Group has expanded its portfolio with the recent acquisition of Bicton Heath Pharmacy in Shropshire.

According to Christie and Co, who brokered the deal, the pharmacy was formerly corporate-owned and was brought to the market as “part of a wider disposal project.”


Located just 2.5 miles from Shrewsbury, Bicton Heath Pharmacy is a standard-hours pharmacy that dispenses an average of 6,600 items monthly, the broker said.

It was purchased by Ravi Nagra, CEO of MSN & Lunts Pharmacy Group, for an undisclosed price.

Nagra's group operates a dozen pharmacies across the West Midlands, serving communities in Shrewsbury, Pontesbury, Craven Arms, Highley, Ludlow in Shropshire, Birmingham, and the Black Country.

Carl Steer, director – pharmacy at Christie and Co, highlighted this acquisition as a potential signal of the start of “a return for small-medium size group operators to the buying landscape.”

“Increasing numbers of group operators seem to be shaping up to return next year or have already secured deals to complete in Q1/Q2 2025,” he said.

Raylane Ltd also recently expanded its portfolio of 10 pharmacies with the acquisition of Evans Pharmacy in Worcestershire.

According to Christie and Co, the pharmacy, which dispenses approximately 10,000 items per month, had been owned by Philip Hawkes for over a decade and was put on the market due to his retirement.

Despite ongoing operational challenges in the pharmacy landscape, Christie and Co anticipates “a record year of activity” in 2024.

“High levels of activity in H2 2024 will already ensure 2025 starts with a bang,” Steer said.

Steer added that while accurate pricing will continue to be key for all sellers, there is “a buoyant market across the Midlands,” which he believes is promising for would-be sellers.

As revealed by Christie and Co’s Pharmacy Market Review 2024, the UK pharmacy market experienced a 3.5 per cent decline, with 505 pharmacies removed from the register—primarily from corporate estates.

Divestment efforts in 2023 led to Rowlands reducing its estate by 15.8 per cent and Boots by 13.2 per cent.

Meanwhile, supermarket chains such as Tesco, Asda, and Morrisons saw smaller reductions.

In contrast, Well Pharmacy expanded its presence, increasing its branch count to 761 pharmacies through the acquisition of 42 pharmacies from the Norchem Group.

The report cited the complete exit of the LloydsPharmacy brand from the high street as the most significant impact on corporate market share.

During its two-year ownership of LloydsPharmacy, AURELIUS oversaw the closure of 1,349 corporate branches.

“Without a doubt, the main beneficiary of this demise has been the independent sector, with existing operators and first-time buyers snapping up opportunities to acquire pharmacies at greatly discounted prices,” the broker stated.

More For You

Cargo plane unloading pharmaceuticals at US airport amid tariff concerns and stockpiling

Imports jumped in particular from Ireland, the top drug exporter to the US

Pic credit: iStock

Pharma imports to US surged in March as drugmakers look to avoid tariffs

Pharmaceutical imports to the US surged in March as drugmakers stocked up ahead of potential US tariffs on their products, which have historically been exempt from such fees.

Total imports of pharmaceutical products exceeded $50 billion in the month - the equivalent of 20 per cent of all pharmaceutical imports in 2024, according to data from a U.S. Commerce Department report on Tuesday.

Keep ReadingShow less
Scottish community pharmacist working in high street pharmacy with supportive environment

The PDA wants investment to reach those who deliver services to patients every day

Pic credit: iStock

Funding boost in Scotland “needs to work for not just pharmacy owners but pharmacists too”, says PDA

An increase in funding for community pharmacies in Scotland needs to lead to a greater focus on supporting pharmacists rather than “simply sustain business models”, according to the Pharmacy Defence Association (PDA).

Earlier this week, Community Pharmacy Scotland (CPS) accepted the Scottish government’s initial financial offer for the 2025/26 fiscal year, securing a guaranteed minimum reimbursement of £120 million for community pharmacies — up from £110 million from 2024/25.

Keep ReadingShow less
GP surgery upgrades for annual appointments

The surgeries will have additional space to “see more patients, boost productivity and improve patient care”

Pic credit: iStock

GP surgery upgrades to create 8.3 million more annual appointments

Over 1,000 GP surgeries will have their premises modernised to meet the needs of a further 8.3 million appointments each year, the government has announced.

Backed by a cash injection of over £102 million, the surgeries will have additional space to “see more patients, boost productivity and improve patient care”.

Keep ReadingShow less
Wales boosts funding for pharmacy-led UTI and sore throat test services

The sore throat test (STTT) and treat service will be widely available

Pic credit: istock

Welsh pharmacies receive funding boost for clinical services

Two key clinical services will be available in 99 per cent of community pharmacies across Wales after a boost in funding.

The sore throat test (STTT) and treat service and the urinary tract infection (UTI) service have both benefitted from contractual negotiations between the Welsh Government and Community Pharmacy Wales (CPW).

Keep ReadingShow less
Paul Bennett
Paul Bennett, CEO, Royal Pharmaceutical Society
Paul Bennett, CEO, Royal Pharmaceutical Society

Pharmacists need to take advantage of independent prescribing pathways, says Bennett

Independent prescribing will be a “significant point” in the history of community pharmacy, according to Royal Pharmaceutical Society chief executive Paul Bennett.

Last month, the RPS announced the launch of a comprehensive new prescribing development programme to support pharmacists across all stages of their prescribing careers.

Keep ReadingShow less